---
figid: PMC4226441__nihms617481f2
figlink: /pmc/articles/PMC4226441/figure/F2/
number: F2
caption: 'Estrogen action in non-small-cell lung cancer can occur through both genomic
  and nongenomic mechanisms in the lung. Nuclear ERs can be activated in a ligand-dependent
  manner by E2 binding to nuclear ERs at estrogen-responsive elements or AP-1 sites
  in the promoters of estrogen-regulated genes. Nongenomic estrogen action in the
  lungs occurs through rapid activation of EGFR in the cell membrane, which occurs
  through activation of Src and MMP cleavage of the EGFR proligands to activate EGFR
  and the ERK and Akt downstream signaling pathways. Both of these mechanisms of estrogen
  action in non-small-cell lung cancer led to cell proliferation and survival. Available
  strategies to target the estrogen signaling pathway for lung cancer treatment or
  prevention are shown in red and include: (A) inhibition of estrogen synthesis with
  aromatase inhibitors, such as anastrozole or exemestane; (B) downregulation of ERs
  using antiestrogens such as fulvestrant; and (C) targeting growth factor pathways
  that are activated by estrogens with agents such as gefitinib or erlotinib. These
  strategies can be used as single agents or in combination.E2: β-estradiol; EGFR:
  EGF receptor; ER: Estrogen receptor; HB: Heparin-binding; MMP: Matrix metalloproteinase.'
pmcid: PMC4226441
papertitle: Targeting the estrogen pathway for the treatment and prevention of lung
  cancer.
reftext: Timothy F Burns, et al. Lung Cancer Manag. 2014 Feb 1;3(1):43-52.
pmc_ranked_result_index: '6844'
pathway_score: 0.9793404
filename: nihms617481f2.jpg
figtitle: Targeting the estrogen pathway for the treatment and prevention of lung
  cancer
year: '2014'
organisms: Homo sapiens
ndex: 7f2461c9-debc-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4226441__nihms617481f2.html
  '@type': Dataset
  description: 'Estrogen action in non-small-cell lung cancer can occur through both
    genomic and nongenomic mechanisms in the lung. Nuclear ERs can be activated in
    a ligand-dependent manner by E2 binding to nuclear ERs at estrogen-responsive
    elements or AP-1 sites in the promoters of estrogen-regulated genes. Nongenomic
    estrogen action in the lungs occurs through rapid activation of EGFR in the cell
    membrane, which occurs through activation of Src and MMP cleavage of the EGFR
    proligands to activate EGFR and the ERK and Akt downstream signaling pathways.
    Both of these mechanisms of estrogen action in non-small-cell lung cancer led
    to cell proliferation and survival. Available strategies to target the estrogen
    signaling pathway for lung cancer treatment or prevention are shown in red and
    include: (A) inhibition of estrogen synthesis with aromatase inhibitors, such
    as anastrozole or exemestane; (B) downregulation of ERs using antiestrogens such
    as fulvestrant; and (C) targeting growth factor pathways that are activated by
    estrogens with agents such as gefitinib or erlotinib. These strategies can be
    used as single agents or in combination.E2: β-estradiol; EGFR: EGF receptor; ER:
    Estrogen receptor; HB: Heparin-binding; MMP: Matrix metalloproteinase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3R6
  - EGFR
  - PIK3R4
  - ARAF
  - SOS1
  - RAF1
  - HRAS
  - KRAS
  - NRAS
  - PIK3CG
  - MAPK1
  - MAPK3
  - OPN3
  - BRAF
  - CYP19A1
  - GRB2
  - MAP2K2
  - MAP2K1
  - HBEGF
  - PIK3R3
  - AKT2
  - AKT1
  - PIK3R5
  - PIK3CA
  - PIK3CD
  - TGFA
  - PIK3CB
  - SOS2
  - AKT3
  - SRC
  - Exemestane
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: Grb2/SOS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS1
  entrez: '6654'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERO
  symbol: ERO
  source: hgnc_alias_symbol
  hgnc_symbol: OPN3
  entrez: '23596'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Aromatase
  symbol: aromatase
  source: hgnc_alias_symbol
  hgnc_symbol: CYP19A1
  entrez: '1588'
- word: Grb2/SOS
  symbol: GRB2
  source: hgnc_symbol
  hgnc_symbol: GRB2
  entrez: '2885'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: HB-EGF
  symbol: HBEGF
  source: hgnc_symbol
  hgnc_symbol: HBEGF
  entrez: '1839'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: TGFA
  symbol: TGFA
  source: hgnc_symbol
  hgnc_symbol: TGFA
  entrez: '7039'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: Grb2/SOS
  symbol: SOS
  source: bioentities_symbol
  hgnc_symbol: SOS2
  entrez: '6655'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Src
  symbol: SRC
  source: hgnc_symbol
  hgnc_symbol: SRC
  entrez: '6714'
chemicals:
- word: Exemestane
  source: MESH
  identifier: C056516
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4226441__F2
redirect_from: /figures/PMC4226441__F2
figtype: Figure
---
